


1

## Aminolevulinic acid dendrimers in photodynamic treatment of cancer and atheromatous disease

L. Rodriguez,\* P. Vallecorsa,\* S. Battah, G. Di Venosa, G. Calvo, L. Mamone, D. Sáenz, M. Gonzalez, A. Battle, A. J. MacRobert and A. Casas

ALA dendrimers are taken up by caveolae-mediated endocytosis in macrophages. Intracellular ALA release gives rise to PpIX synthesis and subsequent photosensitization of key cells in atheromas and tumour diseases.



Please check this proof carefully. **Our staff will not read it in detail after you have returned it.**

Translation errors between word-processor files and typesetting systems can occur so the whole proof needs to be read. Please pay particular attention to: tabulated material; equations; numerical data; figures and graphics; and references. If you have not already indicated the corresponding author(s) please mark their name(s) with an asterisk. Please e-mail a list of corrections or the PDF with electronic notes attached – do not change the text within the PDF file or send a revised manuscript. Corrections at this stage should be minor and not involve extensive changes. All corrections must be sent at the same time.

**Please bear in mind that minor layout improvements, e.g. in line breaking, table widths and graphic placement, are routinely applied to the final version.**

We will publish articles on the web as soon as possible after receiving your corrections; **no late corrections will be made.**

Please return your **final** corrections, where possible within **48 hours** of receipt, by e-mail to: pps@rsc.org

## Queries for the attention of the authors

Journal: **Photochemical & Photobiological Sciences**

Paper: **c5pp00126a**

Title: **Aminolevulinic acid dendrimers in photodynamic treatment of cancer and atheromatous disease**

Editor's queries are marked like this [Q1, Q2, ...], and for your convenience line numbers are indicated like this [5, 10, 15, ...].

Please ensure that all queries are answered when returning your proof corrections so that publication of your article is not delayed.

| Query Reference | Query  | Remarks |
|-----------------|--|---------|
| Q1              | For your information: You can cite this article before you receive notification of the page numbers by using the following format: (authors), Photochem. Photobiol. Sci., (year), DOI: 10.1039/c5pp00126a. |         |
| Q2              | Please carefully check the spelling of all author names. This is important for the correct indexing and future citation of your article. No late corrections can be made.                                  |         |

## Aminolevulinic acid dendrimers in photodynamic treatment of cancer and atheromatous disease†

Cite this: DOI: 10.1039/c5pp00126a

L. Rodriguez,<sup>\*‡a</sup> P. Vallecorsa,<sup>\*‡a</sup> S. Battah,<sup>b,c</sup> G. Di Venosa,<sup>a</sup> G. Calvo,<sup>a</sup> L. Mamone,<sup>a</sup> D. Sáenz,<sup>a</sup> M. Gonzalez,<sup>d</sup> A. Batlle,<sup>a</sup> A. J. MacRobert<sup>c</sup> and A. Casas<sup>a</sup>

The use of endogenous protoporphyrin IX after administration of 5-aminolaevulinic acid (ALA) has led to many applications in photodynamic therapy (PDT). We have previously reported that the conjugation of ALA dendrimers enhances porphyrin synthesis. The first aim of this work was to evaluate the ability of ALA dendrimers carrying 6 and 9 ALA residues (6m-ALA and 9m-ALA) to photosensitise cancer cells. For this aim, we employed LM3 mammary carcinoma cells. In these tumour cells, at low concentrations porphyrin synthesis from dendrimers was higher compared to ALA, whereas at high concentrations, porphyrin synthesis was similar from both compounds. Topical application of ALA dendrimers on the skin overlying a subcutaneous LM3 implanted tumour showed no diffusion of the molecules either to distant skin sites or to the adjacent tumour, suggesting a promising use of the ALA macromolecules in superficial cancer models. As a second objective, we proposed the use of ALA-dendrimers in vascular PDT for the treatment of atherosclerosis. Thus, we focused our studies on ALA-dendrimer's selectivity towards macrophages in comparison with endothelial cells. For this aim we employed Raw 264.7 macrophages and HMEC-1 microvasculature cells. Porphyrin synthesis induced in macrophages by 6m-ALA and 9m-ALA (3 h, 0.025 mM) was 6 and 4.6 times higher respectively compared to the endothelial cell line, demonstrating the high affinity of ALA dendrimers for macrophages. On the other hand, ALA employed at low concentrations was slightly selective (1.7-fold) for macrophages. Inhibition studies suggested that ALA dendrimer uptake in macrophages is mainly mediated by caveolae-mediated endocytosis. Our main conclusion is that in addition to being promising molecules in PDT of superficial cancer, ALA dendrimers may also find applications in vascular PDT, since *in vitro* they showed selectivity to the macrophage component of the atheromatous plaque, as compared to the vascular endothelium.

Received 28th March 2015,  
Accepted 18th May 2015

DOI: 10.1039/c5pp00126a

www.rsc.org/pps

### Introduction

In recent years, (ALA)-mediated photodynamic therapy (PDT) has been an active area of investigation and has become one of the most promising fields in PDT research. ALA is the precursor of the photosensitizer protoporphyrin IX (PpIX). After ALA administration, cells generate PpIX through the haem biosynthetic pathway. The main advantage of PpIX relative to

other photosensitizers is the short half-life of its photosensitizing effects which do not last longer than 48 h.<sup>1,2</sup>

Due to the hydrophilic nature of ALA, ALA-PDT has been hampered by the rate of ALA uptake into neoplastic cells and its limited penetration into tissue. Much effort has therefore been made to overcome the restricted bioavailability of ALA, either by derivatization or by the use of different delivery vehicles.

Macromolecular drug carriers have been shown to increase cellular uptake of the drugs associated with them by promoting endocytosis. In addition, macromolecules are more easily taken up by tumour cells than normal cells, which is believed to arise from the increased permeability of the tumour vasculature to macromolecules and limited lymphatic drainage.<sup>3,4</sup> After internalisation, lysosomal enzymes hydrolyse any ester linkages to release the free drug. Among the available macromolecules, the dendrimers have the advantages of the high drug payload, and the ability to control and modify the size and lipophilicity of the dendrimer-conjugate for optimising cellular uptake and tissue biodistribution.<sup>5,6</sup>

<sup>a</sup>Centro de Investigaciones sobre Porfirinas y Porfirias (CIPYP). CONICET-Htal de Clínicas Gral. José de San Martín, Córdoba 2351 1er subsuelo, Ciudad de Buenos Aires, CP-1120AAF, Argentina. E-mail: adriana@qb.fcen.uba.ar

<sup>b</sup>School of Biological Sciences, University of Essex, Wivenhoe Park CO4 3SQ, UK

<sup>c</sup>Division of Surgery and Interventional Sciences and UCL Institute of Biomedical Engineering, University College London, Charles Bell House, 67-73 Riding House St, London W1W 7EJ, UK

<sup>d</sup>Facultad de Ciencias Médicas, Instituto de Investigaciones Bioquímicas de La Plata (INIBIOLP), CONICET-UNLP, calles 60 y 120, Argentina

†Part of the data in this paper were presented during the 16th International Congress on Photobiology held in Cordoba, Argentina, in September (8th–12th), 2014.

‡Both authors contributed equally to the work.

1 Because ALA is a relatively small molecule, it is a suitable  
candidate for conjugation with macromolecules, such as  
dendrimers. In principle, dendrimeric nanovehicles bearing a  
high ALA 'payload' per molecule can deliver a much higher  
5 quantity of ALA to cells. In previous work, we have designed a  
series of novel ALA-containing dendrimers.<sup>7</sup> These compounds  
contained 3 to 18 ALA residues, and some of them were able to  
induce PpIX synthesis and cell photodamage in cell cultures.  
Those studies indicated more efficient and sustained PpIX  
10 production than ALA at drug equivalent doses after i.p.  
administration.<sup>8–10</sup> In addition, the amino groups of the ALA  
molecules would be protonated *in vivo*, thus conferring good  
water solubility on the dendrimer. In the present work, we  
15 have focused on dendrimers containing 6 and 9 ALA residues  
for delivery of the pro-drug.

In addition to tumour tissue, atherosclerotic plaque has  
been proposed as a suitable target for PDT. Drug lipophilicity  
and high lipid content of vascular plaque were thought to pre-  
20 dictate selective uptake.<sup>11</sup> More specifically, the presence of  
macrophages has been advocated as a reason for the preferential  
accumulation of PSs in the plaque due to the interaction  
of PSs with LDL.<sup>12</sup>

Affinity of porphyrins and phthalocyanines for atherosclero-  
25 tic lesions was reported in the literature several decades  
ago.<sup>13,14</sup> The development of lasers coupled to fibre optics  
enabled the possibility of applying PDT to such lesions. PDT  
of vascular *de novo* atherosclerotic and, potentially, restenotic  
lesions has been employed for the treatment of hyperchole-  
30 sterolemic rabbits<sup>11,13,15,16</sup> and human peripheral arterial  
atherosclerosis<sup>17</sup> showing that photoangioplasty holds promise  
as an alternative intervention for flow-limiting atherosclerosis,  
either alone or as an adjunct to interventional procedures.<sup>18,19</sup>  
Endovascular PDT is also being taken under consideration as a  
35 method to stabilize the vulnerable plaques by inhibiting  
inflammation.<sup>20</sup>

In addition to porphyrins, PDT mediated by ALA was  
employed alone or in combination with angioplasty for endo-  
40 vascular treatment and it proved to be safe and able to reduce  
restenosis following angioplasty.<sup>21–23</sup>

Since macromolecule carriers promote endocytosis of the  
carried drug, we propose the use of ALA dendrimers for selec-  
45 tive accumulation in the macrophage component of the athero-  
matous plaques.

The first aim of the present study was to analyse selective  
accumulation of PpIX formed in tumours from ALA dendri-  
mers employing *in vitro* and *in vivo* models. The second objec-  
50 tive was to compare porphyrin synthesis from ALA dendrimers  
in macrophages and endothelial cells, since they are the most  
important cell types forming the atheromatous plaques.

## 55 Materials and methods

### Chemicals

ALA (MW: 168) and MTT were from Sigma Chem Co. 6m-ALA  
(MW: 1502) and 9m-ALA (MW: 2215) (Fig. 1) were provided by

1 ChemPharm-Research, UK and were freshly prepared in saline  
for *in vivo* experiments or in water for *in vitro* experiments.  
The synthesis of the dendrimers was carried out as published  
5 previously.<sup>7</sup>

### Cell lines

Raw 264.7 macrophages were obtained from ATCC and grown  
10 in DMEM (Gibco BRL, Life Technologies Ltd, Paisley, UK) con-  
taining high glucose and pyruvate, supplemented with 2 mM  
L-glutamine, 40 µg gentamycin per ml<sup>-1</sup> and 5% fetal bovine  
serum. Cells were used 48 h after plating.

LM3 cells derived from the murine mammary adeno-  
15 carcinoma M3<sup>24</sup> were cultured in Eagle's minimum essential  
medium (Gibco Life Technologies Ltd, Paisley, UK), sup-  
plemented with 2 mM L-glutamine, 40 µg gentamycin per ml<sup>-1</sup>  
and 5% fetal bovine serum. Cells were used 48 h after plating.

HMEC-1 human endothelial cells were kindly provided by  
20 Dr E.W. Ades (Centers for Disease Control and Prevention,  
Atlanta, GA). These cells have been immortalised by trans-  
fection of human dermal microvascular endothelial cells with  
a plasmid containing the coding region for the large T antigen  
of the simian virus 40 A.<sup>25</sup> The cells were grown in endothelial  
25 basal medium (EBM-2, Lonza, USA), supplemented with hydro-  
cortisone, 10% serum, hEGF, FBS, VEGF, hFGFB, R3-IGF-1,  
ascorbic acid, heparin and 40 µg gentamycin from Lonza, USA  
as well. Cells were used 48 h after plating.

### PDT treatment

30 Cells were incubated in serum-free medium containing ALA or  
dendrimers and after 3 h, irradiation was performed. After  
irradiation, medium was replaced by ALA-free medium +  
serum, the cells were incubated for another 19 h and then  
35 tested for viability.

### MTT viability assay

40 Phototoxicity and cell viability were documented by the MTT  
assay.<sup>26</sup> This is a method based on the activity of mitochon-  
drial dehydrogenases. Following appropriate treatments, MTT  
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbromide)  
45 solution was added to each well at a concentration of 0.5 mg  
ml<sup>-1</sup>, and plates were incubated at 37° C for 1 h. The resulting  
formazan crystals were dissolved by the addition of DMSO and  
the absorbance was read at 560 nm.

### Light source

50 A bank of 2 fluorescent lamps (Osram L 18W/765) was used.  
The spectrum of light was between 400 and 700 nm with the  
highest radiant power at 600 nm. The plates were located at a  
distance of 14 cm from the light source, and the cells were  
55 irradiated from below. The fluence rate was measured with  
a radiometer (Model 65, Yellow Springs, OH, USA). We used  
fluences of 0.15 or 0.6 J cm<sup>-2</sup> and the power density was  
0.5 mW cm<sup>-2</sup>.




Fig. 1 Structures of ALA and ALA dendrimers.

### Endocytosis inhibition

To assess and quantify the endosome–lysosome fusion process after ALA dendrimer uptake, porphyrin synthesis in Raw cells was evaluated after 90 min uptake of 0.3 mM ALA or dendrimers at 18 °C; and after withdrawal of the ALA compounds, the cells were further incubated for 3 h at 37 °C.

To determine the type of endocytosis involved in ALA dendrimer uptake, Raw cells were exposed to the endocytosis inhibitors as follows: 1 min for 0.1 mM *N*-ethylmaleimide (NEM), 1 h for 10 μg ml<sup>-1</sup> nystatin, 30 min for 10 μg ml<sup>-1</sup> amiloride and 30 min for 0.5 μg ml<sup>-1</sup> chlorpromazine. Afterwards, the compounds were withdrawn and the cells were exposed for 3 h to ALA or dendrimers at 0.3 mM and porphyrins were extracted and quantified.

### Porphyrin extraction from cells

Porphyrins accumulated within the cells were extracted twice with 5% HCl, leaving the cells standing for half an hour in the

presence of the acid at 37 °C. For media determinations, 5% HCl was added and measured directly. These conditions proved to be the optimal for total PpIX extraction. The fluorescence excitation and emission wavelengths were 406 nm and 604 nm, respectively. PpIX (Frontier Scientific, Logan, Utah, USA) was used as a reference standard.

### Animals

Male BALB/c mice of 12 weeks old, weighing 20–25 g, were used. They were provided with food (Purina 3, Molinos Río de la Plata) and water *ad libitum*. A suspension of 1.6 × 10<sup>5</sup> cells of the LM3 line was subcutaneously injected into the right flanks of the mice. Experiments were performed at approximately day 20 after the implantation. Tumours of the same uniform size were employed (1 cm diameter). Animals received humane care and protocols were approved by the Argentinean Committee of Animal Ethics (CICUAL, School of Medicine, University

of Buenos Aires) in full accord with the UK Guidelines for the Welfare of Animals in Experimental Neoplasia.<sup>27</sup>

### ALA and ALA dendrimer administration

For topical administration, ALA or dendrimers were dissolved in 0.2 ml saline immediately before use. The solutions were applied on the tumour, after shaving the hair and rubbing with a smooth paintbrush for a period of 5 min, a time at which no vestige of lotion was visible. Two areas of skin were investigated: skin over the tumour (SOT), and normal skin taken from the opposite flank, denoted as 'distant skin'.

### Fluorescence spectroscopy

*In vivo* fluorescence measurements were carried out for studying kinetics of PpIX formation after topical application of ALA or ALA peptides. A bifurcated fibre-optic probe was coupled to a Perkin-Elmer LS50B fluorescence spectrometer, and fluorescence from the tissue was detected at the probe tip. Excitation light at a wavelength of 407 nm was coupled into one arm of the bifurcated probe, enabling conduction of excitation to the skin surface and collection of the PpIX fluorescence emission *via* the other arm to the spectrometer. Taking into account the attenuation coefficient for skin, the 407 nm light penetrates deep enough into the skin to excite the PpIX in the epidermis and dermis.<sup>28</sup> The fibre tip was fitted with a rubber spacer that ensured a constant fixed distance of 7 mm between the fibre and the tissue and provided optimal signal collection from the tissue. Fluorescence intensity was measured as a function of time and expressed in arbitrary units at an emission wavelength of 635 nm. In addition, fluorescence emission spectra were recorded to verify that the fluorescence signal corresponded to PpIX.

### Porphyrin extraction from tissues

At the time of maximal fluorescence, after ALA or ALA dendrimer application, the animals were sacrificed. Tumour, SOT and distant skin samples were homogenised in a 4 : 1 solution of ethyl acetate :Hglacial acetic acid. The mixtures were centrifuged for 30 min at 3000g, and the supernatants were added to an equal volume of 5% HCl. Extraction with HCl was repeated until there was no detectable fluorescence in the organic layer. The aqueous fraction was used for the determination of porphyrins. For fluorometric determination, a Perkin Elmer LS55 spectrofluorometer was used with an emission wavelength of 604 nm and an excitation wavelength of 406 nm, employing PpIX as the reference standard.


### Statistical analysis

The values in the figures and tables are expressed as mean  $\pm$  standard deviations of the mean. A two-tailed Student's *t*-test was used to determine statistical significance between means. *P* values <0.05 are considered significant.


## Results

We evaluated porphyrin synthesis from ALA and ALA dendrimers in the mammary carcinoma LM3 cell line (Fig. 2). After a 3 h incubation period, both dendrimers induced higher porphyrin synthesis compared to ALA, employed at low concentrations ( $54.02 \pm 2.3$  and  $56.7 \pm 4.2$  ng porphyrins per  $10^5$  cells for 6m-ALA and 9m-ALA respectively and  $15.4 \pm 0.8$  for ALA) at 0.025 mM concentrations. Plateau values are obtained from ALA at 0.3 mM, whereas from the dendrimers they are obtained at a concentration 10 times lower. The higher ALA payload accounts for the higher rate of porphyrin synthesis, though plateau values obtained are similar to ALA and ALA dendrimers (60 porphyrins per  $10^5$  cells).

By employing longer incubation periods of 24 h the profiles of porphyrin synthesis are similar to the 3 h ones. The amount of tetrapyrroles formed from the dendrimers is still significantly higher than the free drug at low concentrations. However, the differences between porphyrins induced by the dendrimers and by ALA are less marked ( $53.9 \pm 4.2$  for ALA;  $98.6 \pm 9.0$  and  $101.0 \pm 8.2$  ng porphyrins per  $10^5$  cells for 6m-ALA and 9m-ALA respectively) at 0.05 mM concentrations. Plateau values are obtained for both ALA and ALA dendrimers



**Fig. 2** Porphyrin synthesis from ALA or ALA dendrimers in LM3 cells. Cells were exposed to different concentrations of ALA or ALA dendrimers during 3 h (A) or 24 h (B). Intracellular porphyrin levels were determined fluorometrically and normalised per number of cells present at the beginning of the experiment.



**Fig. 3** LM3 cell survival after PDT cells were incubated with 0.025 mM ALA or ALA dendrimers during 3 h. Afterwards, PDT ( $0.15 \text{ J cm}^{-2}$ ) was performed, and cell viability was evaluated by the MTT assay, as percentage of control non-irradiated cells.


at higher concentrations as compared to 3 h incubation, as substrate consumption and maximal PpIX synthesis is around  $140 \text{ ng porphyrins per } 10^{-5} \text{ cells}$  for the three compounds tested.

In line with the patterns of porphyrin synthesis, Fig. 3 shows that the higher the amount of porphyrins, the higher the photocytotoxicity for a given dose comparing ALA with ALA dendrimers. PDT was applied after 3 h incubation with ALA or dendrimers at 0.025 mM, which is a plateau concentration for ALA dendrimers but not for ALA. Under these conditions, ALA induces 50% cellular killing whereas 85 to 90% is obtained employing the dendrimers.

By means of fibre-optic fluorescence detection, we analysed porphyrin formation as a function of time after topical application of ALA and ALA dendrimers on the skin overlying the tumour (SOT) of the implanted mice (Fig. 4A). For comparison of the porphyrin production generated by the dendrimer *versus* ALA, doses of 5 mg of ALA, 7.45 mg of 6m-ALA and 7.32 mg of 9m-ALA were used. These ALA dendrimer doses were used to deliver a drug equivalent dose to ALA, since each dendrimer moiety incorporates 6 or 9 ALA residues respectively.

ALA induces similar profiles of porphyrin production in SOT as compared to distant skin, this being a consequence of rapid diffusion of the molecule to other sites. On the other hand, both dendrimers induce lower amounts of porphyrins in distant skin and higher in SOT as compared to ALA.

Fig. 4B depicts the amount of porphyrins formed 3 h and 4 h after topical application of ALA and ALA dendrimers respectively. Measurements were carried out in tumour, SOT and distant skin after chemical extraction at the plateau times calculated from Fig. 4A. Whereas both tumour and distant skin porphyrins synthesised from ALA dendrimers are much lower compared to ALA, SOT values are significantly higher for




**Fig. 4** Porphyrin synthesis in the skin over the tumour and the distant skin after topical application of ALA and ALA dendrimers. ALA and ALA dendrimers were applied topically in equimolar concentrations of 5 mg ALA to the SOT. At different times after application, the porphyrin fluorescence was monitored using a fibre optic probe coupled to a fluorescence spectrometer. Measurements were made on the skin overlying the tumour and over a distant skin area. We herein show the average of three mice per treatment (A). Porphyrin accumulation determined by chemical extraction in tumours, the skin overlying the tumour, and a distant skin site of 3 mice killed at the plateau times obtained from A (B). \* $p < 0.05$  as compared to ALA.


the latter, which represents its selective limitation to the area of application, without diffusing to tumour areas.

We also evaluated porphyrin synthesis from ALA and ALA dendrimers in the Raw macrophages 264.7 as well as in the endothelial HMEC-1 cell line (Fig. 5 and 6). After a 3 h incubation period, both dendrimers induced in Raw cells higher porphyrin synthesis compared to ALA, employed at low concentrations ( $32 \pm 3$  for ALA;  $145 \pm 12$  and  $147 \pm 10 \text{ ng porphyrins per } 10^{-5} \text{ cells}$  for 6m-ALA and 9m-ALA respectively) at 0.025 mM concentrations. Plateau values (around  $160 \text{ ng porphyrins per } 10^{-5} \text{ cells}$ ) are obtained from ALA at 0.2 mM, whereas from the dendrimers they are obtained at 0.025 mM, which has an 8 times lower concentration (Fig. 5). After 24 h incubation, overall porphyrin synthesis is significantly increased. At 0.05 mM, ALA induces  $68 \pm 6 \text{ ng porphyrins per } 10^{-5} \text{ cells}$ , whereas  $146 \pm 12$  and  $280 \pm 25$  are obtained from 9m-ALA and 6m-ALA respectively.

Similarly, porphyrins induced from low dendrimer concentrations at 3 h are also higher in HMEC-1 cells (Fig. 6) com-



**Fig. 5** Porphyrin synthesis from ALA or ALA dendrimers in Raw 264.7 cells. Cells were exposed to different concentrations of ALA or ALA dendrimers during 3 h (A) or 24 h (B). Intracellular porphyrin levels were determined fluorometrically and normalised per number of cells present at the beginning of the experiment.



**Fig. 6** Porphyrin synthesis from ALA or ALA dendrimers in HMEC-1 cells. Cells were exposed to different concentrations of ALA or ALA dendrimers during 3 h (A) or 24 h (B). Intracellular porphyrin levels were determined fluorometrically and normalised per number of cells present at the beginning of the experiment.

pared to ALA. Porphyrin values of  $20 \pm 2$  for ALA;  $24 \pm 2$  and  $32 \pm 2$  ng per  $10^5$  cells for 6m-ALA and 9m-ALA respectively are obtained at 0.025 mM concentrations. Plateau values obtained from 6m-ALA but not from 9m-ALA are significantly higher than those obtained from ALA.

Employing longer incubation times of 24 h, the differences between porphyrins obtained from ALA and those produced by the dendrimers are more marked. Porphyrin values of  $68 \pm 5$  for ALA;  $129 \pm 12$  and  $132 \pm 13$  ng per  $10^5$  cells for 6m-ALA and 9m-ALA respectively are obtained at 0.05 mM concentrations, and plateau values obtained are 3 times higher than those obtained at the 3 h time point.

In order to assess the selectivity of the dendrimers for the macrophage cells, we calculated the ratio between PpIX synthesised by the macrophages and the endothelial cells at a given concentration (Table 1). The ratio calculated for the 3 h incubation period with ALA is 1.7, whereas the values for the 6m-ALA and 9m-ALA are 6.0 and 4.6 respectively, showing that the ALA dendrimers are largely more selective than the free molecule for the macrophages. In contrast, at longer incubation time periods, the ratios drop to 2.1 and 1.1 for 6m-ALA and 9m-ALA respectively, whereas 1 is the ratio obtained for ALA.

Employing 3 h incubation period in the presence of 0.025 mM of ALA or dendrimers, PDT induces mild conditions

**Table 1** Porphyrin synthesis ratios between macrophages and endothelial cells exposed to ALA or dendrimers<sup>a</sup>


|   | ALA | 6m-ALA | 9m-ALA |
|---|-----|--------|--------|
| Macrophages/endothelial cells at 3 h (0.025 mM) | 1.7 | 6.0    | 4.6    |
| Macrophages/endothelial cells at 24 h (0.05 mM) | 1.0 | 2.1    | 1.1    |

<sup>a</sup> The ratios of porphyrin synthesis are calculated on the basis of the values of 0.025 and 0.05 mM for time incubation periods of 3 and 24 h respectively taken from Fig. 5 and 6.

of cell death for HMEC-1 cells, whereas macrophages treated with ALA dendrimers but not with ALA are completely killed (Fig. 7).

Since the ALA payload of the dendrimers is much higher, we calculated the amount of ALA delivered by the dendrimers expressed in molar equivalents of ALA (Table 2), and we listed a set of porphyrin synthesis values taken from Fig. 2, 5 and 6 in order to establish an accurate comparison. It appears that at low 6m-ALA concentrations (lower than plateau values), the amount of porphyrins synthesised by LM3 and Raw cells is





**Fig. 7** HMEC-1 and Raw264.7 cell survival after PDT. Cells were incubated with 0.025 mM ALA or ALA dendrimers during 3 h. Afterwards, PDT ( $0.6 \text{ J cm}^{-2}$ ) was performed, and cell viability was evaluated by the MTT assay, as the percentage of control non-irradiated cells.

**Table 2** ALA equivalent dose delivered by the dendrimers (amount of ALA, as expressed in the ALA molar equivalent value) according to the prodrug concentration and porphyrin synthesis in the different cell lines at 3 h (expressed as ng porphyrins per  $10^{-5}$  cells)

| Prodrugs | Prodrugs (mM) | ALA molar equivalent (mM) | LM3  | Raw  | HMEC-1 |
|----------|---------------|---------------------------|------|------|--------|
| ALA      | 0.005         | 0.005                     | 6.66 | 12.2 | 2.0    |
|          | 0.01          | 0.01                      | 8.2  | 22.3 | 17.0   |
|          | 0.05          | 0.05                      | 27.1 | 82.1 | 22.3   |
|          | 0.1           | 0.1                       | 41.6 | 100  | 26.1   |
|          | 0.5           | 0.5                       | 60.1 | 153  | 32.7   |
| 6m-ALA   | 0.005         | 0.03                      | 18.7 | 50.2 | 5.3    |
|          | 0.01          | 0.06                      | 43.9 | 112  | 16.2   |
|          | 0.05          | 0.3                       | 56.3 | 156  | 28.5   |
|          | 0.1           | 0.6                       | 58.0 | 156  | 36.2   |
|          | 0.5           | 3                         | 63.4 | 162  | 44.9   |
| 9m-ALA   | 0.005         | 0.045                     | 23.1 | 62.1 | 6.7    |
|          | 0.01          | 0.09                      | 42.5 | 112  | 18.4   |
|          | 0.05          | 0.45                      | 58.1 | 149  | 34.2   |
|          | 0.1           | 0.9                       | 56.8 | 159  | 34.3   |
|          | 0.5           | 4.5                       | 62.4 | 168  | 36.8   |

higher than that obtained from ALA, whereas 9m-ALA induces similar porphyrin values as compared to ALA, even at low concentrations. In contrast, ALA dendrimers seem to be less efficient than ALA in HMEC-1 cells, throughout the concentration range assayed.

To gain insight into the mechanisms of endocytosis, Raw cells were pre-treated with drugs that selectively inhibit clathrin-dependent endocytosis (chlorpromazine), caveolae-dependent endocytosis (nystatin and NEM), and macropinocytosis (amiloride) before being exposed to the ALA dendrimers (Table 3). Possible drug-induced cytotoxic effects were

**Table 3** Percentage of endocytosis inhibition in Raw 264.7 macrophages<sup>a</sup>

|                          | ALA           | 6m-ALA         | 9m-ALA         |
|--------------------------|---------------|----------------|----------------|
| <i>N</i> -Ethylmaleimide | $10 \pm 1.1$  | $46 \pm 6.2$   | $43.7 \pm 5.3$ |
| Nystatin                 | $8.7 \pm 0.9$ | $40 \pm 3.8$   | $35.9 \pm 3.4$ |
| Amiloride                | $7.1 \pm 0.5$ | $7.9 \pm 0.9$  | $3.9 \pm 5.1$  |
| Chlorpromazine           | $2.9 \pm 0.4$ | $12.7 \pm 1.1$ | $11.7 \pm 1.8$ |
| 18 °C                    | $8.3 \pm 0.7$ | $48.3 \pm 5.3$ | $38.3 \pm 4.2$ |

<sup>a</sup> Raw 264.7 cells were preincubated with the endocytosis inhibitors and subsequently incubated with 0.3 mM ALA or dendrimers. After 3 h of incubation, porphyrin synthesis was evaluated. Alternatively, the macrophages were incubated for 3 h at 18 °C in the presence of ALA or dendrimers, which were withdrawn and afterwards porphyrin synthesis was evaluated. The percentage of endocytosis inhibition was inferred from the decrease of porphyrin synthesis.

assessed by MTT cell viability assays and observation of cellular morphological changes. Minimal cellular cytotoxicity was observed in drug-treated cells throughout the spectra of concentrations used in these experiments.

Employing caveolae-mediated endocytosis inhibitors, porphyrin synthesis from both dendrimers was impaired 35–45%, thus showing that this process is involved in the uptake of the dendrimers. On the other hand, neither macropinocytosis nor clathrin-mediated endocytosis was related to the process.

It has been previously demonstrated that the transport between endosomes and lysosomes is blocked at approximately 18 °C.<sup>29,30</sup> Accordingly, whether this incubation temperature could block the transport of dendrimers from endosomes to lysosomes in the Raw macrophages was evaluated. We observed a 48% and 38% inhibition of porphyrin synthesis for 6m-ALA and 9m-ALA respectively by blocking endosome–lysosome fusion.

## Discussion

Improved targeting to solid tumours can be achieved by conjugation of anticancer drugs to macromolecules such as dendrimers.<sup>31</sup> In the present work we found that ALA dendrimers are promising in the treatment of superficial cancers since they induce high amounts of PpIX in the area of application with minimal diffusion to distant tissues. The ratios between SOT and distant normal skin porphyrins are 1.1 for ALA, 2.1 for 6m-ALA and 2.5 for 9m-ALA, thus showing a marked confinement to the site of application of the dendrimers, though the diffusion from the SOT to the adjacent tumour is minimal.

The compound 6m-ALA with shorter branches than the current compound has previously been instilled into rat bladder tumours,<sup>32</sup> and it was found that fluorescence ratios between tumour to normal urothelium were around 1.2, and tumour to muscle were 2.0, which is very similar to the ratios obtained employing ALA hexyl ester. In addition, 6m-ALA showed higher penetration depths and absence of systemic reabsorption.

1 After topical administration of the dendrimers, the time of  
maximum porphyrin levels appeared to be delayed compared  
to ALA application by about 1 h. We have found a similar  
behaviour for the 3m-ALA dendrimer,<sup>8</sup> and we have ascribed it  
5 to the retention of the more lipophilic dendron within the  
stratum corneum at the application site.

The role of the stratum corneum retention appears to be  
crucial in the use of ALA esters and ALA dendrimers. For 6m-  
ALA and 9m-ALA we found that skin sites distant from the site  
of topical application exhibited significantly lower porphyrin  
10 levels than ALA. We have previously found this pattern for the  
3m-ALA dendron,<sup>8</sup> as well as for the hexyl ester derivative of  
ALA.<sup>33</sup> Slow hydrolysis of ALA from dendrimers has been pre-  
viously reported *in vivo* for 6m-ALA in tumour cells.<sup>32</sup> In con-  
15 trast, gradual release of the ALA residue from the dendrimer  
has not been observed for topical application of dendrimers.<sup>8</sup>

We have previously found that PpIX levels generated from  
the dendrimer-containing 18 ALAs, 18m-ALA, were signifi-  
cantly decreased by pre-treatment with the macropinocytosis  
inhibitor 5-(*N*-ethyl-*N*-isopropyl)amiloride, whereas NEM eli-  
cited no significant effect.<sup>9</sup> However, the entry and subsequent  
trafficking of the nanoparticles can both depend on the cell  
20 type and the particle charge and size.<sup>34</sup> In the present work we  
found that caveolae-mediated endocytosis is involved in 6m-  
ALA and 9m-ALA uptake, whereas neither macropinocytosis  
nor clathrin-mediated endocytosis is associated with the ALA  
dendrimer's entry into the macrophages. However, this is not  
surprising, since it has previously been reported for PAMAM  
25 dendrimers that the entry mechanism appeared to depend on  
the dendrimer generation, with the smaller dendrimers taken  
up by clathrin-dependent endocytosis and the bigger ones by  
multiple routes.<sup>35,36</sup>

There are several different types of endocytosis, all based  
on formation of intracellular vesicles following invagination of  
the plasma membrane or ruffling giving rise to larger vesicles.  
These endocytic pathways are distinguished by specific molec-  
ular regulators.<sup>37</sup> Two main pathways have been identified for  
40 receptor-mediated endocytosis: the clathrin-dependent and  
the caveolae/lipid raft-dependent endocytic pathways. Clathrin-  
dependent endocytosis is the most well characterized mechan-  
ism for mediating the internalization of membrane receptors  
into cells. It is also important for intracellular trafficking at the  
45 *trans*-Golgi network and endosomes. Caveolae/raft-dependent  
endocytosis is involved in multiple biological processes,  
including virus entry into host cells, internalising glycophos-  
phatidyl inositol-anchored proteins and regulating certain  
signalling cascades.<sup>38</sup> Macropinocytosis is a special case of cla-  
50 thrin-, caveolae- and dynamin-independent endocytosis, which  
is initiated by transient activation of receptor tyrosine kinases  
by growth factors. The receptor activation mediates a signal-  
ling cascade that leads to changes in the actin cytoskeleton  
and triggers the formation of membrane ruffles. These mem-  
brane ruffles protrude to engulf the surrounding fluid and  
55 nutrients in the extracellular milieu.<sup>39</sup> All of these endocytic  
pathways have been shown to be involved in the uptake of  
nanomedicines.<sup>37</sup>

Cell-specific differences also play a role in the uptake of  
1 macromolecules: different kinds of dendrimers have been  
taken up by clathrin-mediated endocytosis in Caco-2 cells<sup>35</sup>  
and by macropinocytosis in A549 cells.<sup>40,41</sup> In addition, gene  
5 delivery by dendrimers has been also shown to use different  
internalisation pathways in different cells, but that caveolae  
form a preferential route.<sup>42,43</sup>

In addition, clathrin-mediated endocytosis, caveolae-  
mediated endocytosis, and macropinocytosis processes have  
10 been shown to be active in Raw 264.7 macrophages, and  
involved in the uptake of micellar nanoparticles independently  
of the molecules charge.<sup>44</sup> Similarly, there are several main  
endocytic pathways in endothelial cells, including clathrin-  
and caveolae-mediated endocytosis, phagocytosis and macro-  
15 pinocytosis. The latter may be of interest for intracellular drug  
delivery to endothelial cells involved in inflammation.<sup>45,46</sup>  
However, macrophages incorporate ALA dendrimers at rates of  
6 or 4.6 times higher than HMEC-1 endothelial cells, thus  
20 showing that the higher endocytic ability of the macrophages  
accounts for ALA dendrimers selectivity.

Even though, caveolae are present in many cell types they  
are especially abundant in endothelial cells. Another major  
difference is that the caveolar uptake is a non-acid and has no  
digestive route of internalization. In addition, evidence for  
caveolin expression in macrophages has been scarce and con-  
flicting,<sup>47</sup> however caveolin-1 mRNA was detected in Raw  
25 264.7 macrophages.<sup>48</sup> Caveolae do not suffer a drop in pH, and  
most molecules that are internalised by caveolae can be  
directly transported to the Golgi and/or endoplasmic reticu-  
lum, thus avoiding normal lysosomal degradation.<sup>49</sup> This  
implies that acidic esterases would not be involved at all in the  
30 release of ALA residues from the dendrimers.

The capability to selectively kill macrophages has appli-  
cations in treating cancer and in the detection and therapy of  
35 vulnerable atherosclerotic plaque and possibly for auto-  
immune disease and some infections.<sup>50</sup> The efficacy of vascu-  
lar PDT should be based on the selective accumulation of  
photosensitizer by atheromatous plaque and optimum drug-  
light interval. Differential kinetics of PpIX formation in the  
40 different cell types of a plaque was demonstrated by Jenkins  
*et al.*<sup>51</sup> After ALA administration to normal pigs, PpIX fluo-  
rescence peaked in the adventitia, intima and medial layers at  
1.5, 4 and 6 h respectively. At 6 h after ALA administration the  
45 ratio of media (muscle cells): intima (endothelium) PpIX was  
about 2.

In the present work, *in vitro* studies employing Raw  
264.7 macrophages and HMEC-1 endothelial cells suggested  
50 that ratios of porphyrin synthesis of 1.7 for macrophage-endo-  
thelial cells from ALA are improved. The ratios obtained at 3 h  
and 0.025 mM concentrations are 6.0 and 4.6 for 6m-ALA and  
9m-ALA respectively, suggesting that the dendrimers are better  
tools than ALA to selectively destroy atheromatous plaques by  
55 means of vascular PDT.

In the process of PpIX synthesis from ALA dendrimers,  
several steps are involved: (a) dendrimer entry into the cells,  
(b) enzymatic hydrolysis and release of ALA, (c) PpIX synthesis

by six enzymes of the haem biosynthetic pathway. We calculated the amount of ALA delivered from the dendrimers expressed in molar equivalents of ALA, and we found that in both tumour and macrophage cells the dendrimers are more efficient than ALA at low concentrations. This has been previously found in other tumour cells for ALA esters and dendrons,<sup>8,33</sup> and is highly influenced by the importance of the pro-drug entry into the cells.

At longer incubation time periods, the differences between the drug and the prodrugs become minimal, and this may be due to a major and limiting role of the PpIX synthesis step rather than the ALA or pro-ALA entry step. In previous work we have found that at high (plateau) concentrations, the regulation of ALA conversion into porphyrins is driven by the enzyme porphobilinogenase.<sup>52</sup>

On the other hand, for HMEC-1 cells the dendrimers do not enhance PpIX production from ALA even at low concentrations, and we ascribe this to their low endocytic ability.

Considering the different ALA payloads of both dendrimers and the similarity of the porphyrin synthesis curves as a function of the prodrug concentration for the three cell lines and both time points analysed, we conclude that hydrolysis from 9m-ALA is not complete, and that 6m-ALA is an equal or better PpIX producer than the 9 ALA containing dendrimer.

In animal models, it was shown that after ALA administration, the fluorescence intensity of PpIX in the atheromatous plaque reached the peak 2 h after injection and was around 10 to 12 times higher than that of adjacent normal vessel segments, having a positive correlation with the macrophage content.<sup>53,54</sup> In addition, Peng *et al.*<sup>53</sup> demonstrated that the ALA-derived PpIX can be employed to reflect the macrophage content in the plaque, and that ALA-PDT could reduce the macrophage content.

In addition to its potential use for PDT of cancer, the key conclusion of this work is that ALA dendrimer mediated photoangioplasty is a promising alternative for the treatment of cardiovascular obstructive diseases. Animal model studies employing ALA dendrimers are needed to further assess the selectivity of PpIX from dendrimers in atheromatous plaques, as well as further extend our studies to vascular smooth muscle cells.

## Abbreviations

|      |   |
|------|---|
| ALA  | 5-Aminolevulinic acid   |
| MTT  | (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbromide) |
| PDT  | Photodynamic therapy  |
| PpIX | Protoporphyrin IX   |

## Acknowledgements

This research was supported by the CONICET, Agencia Nacional de Promoción Científica y Tecnológica Argentina PICT 2010-0772, PICT 2008-0047 and CONICET PIP no.

11220100100173. AJM and SB acknowledge the support of the Biotechnology and Biological Sciences Research Council (BBSRC) grant number E17987.

## References

- 1 J. Kennedy, R. Pottier and G. Pross, Photodynamic Therapy with endogenous protoporphyrin IX: basic principles and present clinical experience, *J. Photochem. Photobiol., B*, 1990, **6**, 143–148.
- 2 H. Fukuda, A. Casas, F. Chueke, S. Paredes and A. Batlle, Photodynamic action of endogenously synthesized porphyrins from aminolevulinic acid, using a new model for assaying the effectiveness of tumoral cell killing, *Int. J. Biochem.*, 1993, **25**, 1395–1398.
- 3 J. Kopecek, P. Kopeckova, T. Minko and Z. Lu, HPMA copolymer anticancer drug conjugates: design, activity, and mechanism of action, *Eur. J. Pharm. Biopharm.*, 2000, **50**, 61–81.
- 4 R. Mehvar, Recent trends in the use of polysaccharides for improved delivery of therapeutic agents: pharmacokinetic and pharmacodynamic perspectives, *Curr. Pharm. Biotechnol.*, 2003, **4**, 283–302.
- 5 U. Boas and P. Heegaard, Dendrimers in drug research, *Chem. Soc. Rev.*, 2004, **33**, 43–63.
- 6 T. McCarthy, P. Karellas, S. Henderson, M. Giannis, D. O'Keefe, G. Heery, J. Paul, B. Matthews and G. Holan, Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention, *Mol. Pharmacol.*, 2005, **2**, 312–318.
- 7 S. Battah, C. Chee, H. Nakanishi, S. Gerscher, A. MacRobert and C. Edwards, Synthesis and biological studies of 5-aminolevulinic acid-containing dendrimers for photodynamic therapy, *Bioconjugate Chem.*, 2001, **12**, 980–988.
- 8 G. M. Di Venosa, A. G. Casas, S. Battah, P. Dobbin, H. Fukuda, A. J. MacRobert and A. Batlle, Investigation of a novel dendritic derivative of 5-aminolaevulinic acid for photodynamic therapy, *Int. J. Biochem. Cell Biol.*, 2006, **38**, 82–91.
- 9 S. Battah, S. Balaratnam, A. Casas, S. O'Neill, C. Edwards, A. Batlle, P. Dobbin and A. J. MacRobert, Macromolecular delivery of 5-aminolaevulinic acid for photodynamic therapy using dendrimer conjugates, *Mol. Cancer Ther.*, 2007, **6**, 876–885.
- 10 A. Casas, S. Battah, G. Di Venosa, P. Dobbin, L. Rodriguez, H. Fukuda, A. Batlle and A. J. MacRobert, Sustained and efficient porphyrin generation in vivo using dendrimer conjugates of 5-ALA for photodynamic therapy, *J. Controlled Release*, 2009, **135**, 136–143.
- 11 S. G. Rockson, P. Kramer, M. Razavi, A. Szuba, S. Filardo, P. Fitzgerald, J. P. Cooke, S. Yousuf, A. R. DeVault, M. F. Renschler and D. C. Adelman, Photoangioplasty for human peripheral atherosclerosis: results of a phase I trial of photodynamic therapy with motexafin lutetium (Antrin), *Circulation*, 2000, **102**, 2322–2324.

- 12 M. R. Hamblin and E. L. Newman, On the mechanism of the tumour-localising effect in photodynamic therapy, *J. Photochem. Photobiol., B*, 1994, **23**, 3–8.
- 13 R. Straight, G. Vincent and E. Hammond, Porphyrin retention and photodynamic treatment of diet induced atherosclerotic lesions in pig, in *Photodynamic Therapy of Tumors and Other Diseases*, ed. G. Jori and C. Perria, LibreriaProgetto, Padova, Italy, 1986, pp. 350–352.
- 14 M. Eldar, Y. Yerushalmi and E. Kessler, Preferential uptake of a water soluble phthalocyanin by atherosclerotic plaques in rabbits, *Atherosclerosis*, 1990, **84**, 135–139.
- 15 S. W. Young, K. W. Woodburn and M. Wright, Lutetium texaphyrin (PCI- 0123): a near-infrared, water-soluble photosensitizer, *Photochem. Photobiol.*, 1996, **63**, 892–897.
- 16 M. Miller, R. Kuntz and S. Friedrich, Frequency and consequences of intimal hyperplasia in specimens retrieved by directional atherectomy of native primary coronary artery stenoses and subsequent restenosis, *Am. J. Cardiol.*, 1993, **71**, 652–658.
- 17 S. G. Rockson, D. P. Lorenz, W. F. Cheong and K. W. Woodburn, Photoangioplasty: An emerging clinical cardiovascular role for photodynamic therapy, *Circulation*, 2000, **102**, 591–596.
- 18 N. Kipshidze and H. Sahota, Photoangioplasty recount: clear punch or dimpled chad?, *Circulation*, 2001, **104**, 55–56.
- 19 M. Pai, W. Jamal, A. Mosse, C. Bishop, S. Bown and J. R. McEwan, Inhibition of in-stent restenosis in rabbit iliac arteries with photodynamic therapy, *Eur. J. Vasc. Endovasc. Surg.*, 2005, **30**, 573–581.
- 20 M. Drakopoulou, K. Toutouzas, A. Michelongona, D. Tousoulis and C. Stefanadis, Vulnerable plaque and inflammation: potential clinical strategies, *Curr. Pharm. Des.*, 2011, **17**, 4190–4209.
- 21 M. P. Jenkins, G. A. Buonaccorsi, M. Raphael, I. Nyamekye, J. R. McEwan, S. G. Bown and C. C. R. Bishop, Clinical study of adjuvant photodynamic therapy to reduce restenosis following angioplasty, *Br. J. Surg.*, 1999, **86**, 1258–1263.
- 22 M. P. Jenkins, G. A. Buanoaccorsi, R. Mansfield, C. C. R. Bishop, S. G. Bown and J. R. McEwan, Reduction in the response to coronary and iliac artery injury with photodynamic therapy using 5-aminolevulinic acid, *Cardiovasc. Res.*, 2000, **45**, 478–485.
- 23 R. J. Mansfield, M. P. Jenkins, M. L. Pai, C. C. Bishop, S. G. Bown and J. R. McEwan, Long-term safety and efficacy of superficial femoral artery angioplasty with adjuvant photodynamic therapy to prevent restenosis, *Br. J. Surg.*, 2002, **89**, 1538–1539.
- 24 S. Werbajh, A. Urtreger, L. Puricelli, E. de Lustig, E. Bal de Kier Joffe and A. R. Kornblihtt, Downregulation of fibronectin transcription in highly metastatic adenocarcinoma cells, *FEBS Lett.*, 1998, **440**, 277–281.
- 25 E. W. Ades, F. J. Candal, R. A. Swerlick, V. G. George, S. Summers, D. C. Bosse and T. J. Lawley, HMEC-1: establishment of an immortalized human microvascular endothelial cell line, *J. Invest. Dermatol.*, 1992, **99**, 683–690.
- 26 F. Denizot and R. Lang, Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability, *J. Immunol. Methods*, 1986, **89**, 271–277.
- 27 P. Workman, E. Aboagye, F. Balkwill, A. Balmain, G. Bruder, D. Chaplin, J. Double, J. Everitt, D. Farningham, M. Glennie, L. Kelland, V. Robinson, I. Stratford, G. Tozer, S. Watson, S. Wedge and S. Eccles, Committee of the National Cancer Research Institute, Guidelines for the welfare and use of animals in cancer research, *Br. J. Cancer*, 2010, **102**, 1555–1577.
- 28 J. Van den Akker, V. Iani, W. Star, H. Sterenberg and J. Moan, Topical application of 5-aminolevulinic acid hexyl ester and 5-aminolevulinic acid to normal nude mouse skin: Differences in protoporphyrin IX fluorescence kinetics and the role of the stratum corneum, *Photochem. Photobiol.*, 2000, **72**, 681–689.
- 29 B. van Deurs, O. W. Petersen, S. Olsnes and K. Sandvig, Delivery of internalized ricin from endosomes to cisternal Golgi elements is a discontinuous, temperature-sensitive process, *Exp. Cell Res.*, 1987, **171**, 137–152.
- 30 W. A. Dunn, A. L. Hubbard and N. N. Aronson Jr., Low temperature selectively inhibits fusion between pinocytotic vesicles and lysosomes during heterophagy of 125I-asialofetuin by the perfused rat liver, *J. Biol. Chem.*, 1980, **255**, 5971–5978.
- 31 M. Gunther, E. Wagner and M. Ogris, Specific targets in tumor tissue for the delivery of therapeutic genes, *Curr. Med. Chem.: Anti-Cancer Agents*, 2005, **5**, 157–571.
- 32 A. François, S. Battah, A. J. MacRobert, L. Bezdetnaya, F. Guillemain and M. A. D'Hallewin, Fluorescence diagnosis of bladder cancer: a novel in vivo approach using 5-aminolevulinic acid (ALA) dendrimers, *BJU Int.*, 2012, **110**, 1155–1162.
- 33 C. Perotti, H. Fukuda, G. DiVenosa, A. J. MacRobert, A. Batlle and A. Casas, Porphyrin synthesis from ALA derivatives for photodynamic therapy. In vitro and in vivo studies, *Br. J. Cancer*, 2004, **90**, 1660–1665.
- 34 G. Sahay, D. Y. Alakhova and A. V. Kabanov, Endocytosis of nanomedicines, *J. Controlled Release*, 2010, **145**, 182–195.
- 35 K. M. Kitchens, A. B. Foraker, R. B. Kolhatkar, P. W. Swaan and H. Ghandehari, Endocytosis and interaction of poly (amidoamine) dendrimers with Caco-2 cells, *Pharm. Res.*, 2007, **24**, 2138–2145.
- 36 F. P. Seib, A. T. Jones and R. Duncan, Comparison of the endocytic properties of linear and branched PEIs, and cationic PAMAM dendrimers in B16f10 melanoma cells, *J. Controlled Release*, 2007, **117**, 291–300.
- 37 T. G. Iversen, T. Skotland and K. Sandvig, Endocytosis and intracellular transport of nanoparticles: Present knowledge and need for future studies, *Nano Today*, 2011, **6**, 176–185.
- 38 X. D. Zhu, Y. Zhuang, J. J. Ben, L. L. Qian, H. P. Huang, H. Bai, J. H. Sha, Z. G. He and Q. Chen, Caveolae-dependent endocytosis is required for class A macrophage scavenger receptor-mediated apoptosis in macrophages, *J. Biol. Chem.*, 2011, **286**, 8231–8239.

- 1 39 J. Mercer and A. Helenius, Virus entry by macropinocytosis, *Nat. Cell Biol.*, 2009, **11**, 510–520.
- 5 40 O. P. Perumal, R. Inapagolla, S. Kannan and R. M. Kannan, The effect of surface functionality on cellular trafficking of dendrimers, *Biomaterials*, 2008, **29**, 3469–3476.
- 10 41 E. Fröhlich, The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles, *Int. J. Nanomed.*, 2012, **7**, 5577–5591.
- 15 42 M. Manunta, P. H. Tan, P. Sagoo, K. Kashefi and A.J. George, Gene delivery by dendrimers operates via a cholesterol dependent pathway, *Nucleic Acids Res.*, 2004, **32**, 2730–2739.
- 20 43 M. Manunta, B. J. Nichols, P. H. Tan, P. Sagoo, J. Harper and A. J. George, Gene delivery by dendrimers operates via different pathways in different cells, but is enhanced by the presence of caveolin, *J. Immunol. Methods*, 2006, **314**, 134–146.
- 25 44 K. Xiao, Y. Li, J. Luo, J. S. Lee, W. Xiao, A. M. Gonik, R. G. Agarwal and K. S. Lam, The effect of surface charge on in vivo biodistribution of PEG-oligocholeic acid based micellarnanoparticles., *Biomaterials*, 2011, **32**, 3435–3446.
- 30 45 S. Muro, M. Koval and V. Muzykantov, Endothelial endocytic pathways: gates for vascular drug delivery, *Curr. Vasc. Pharmacol.*, 2004, **2**, 281–299.
- 35 46 R. V. Stan, Endocytosis pathways in endothelium: how many?, *Am. J. Physiol.: Lung Cell. Mol. Physiol.*, 2006, **290**, 806–808.
- 40 47 M. G. Lei and D. C. Morrison, Differential expression of caveolin-1 in lipopolysaccharide-activated murine macrophages, *Infect. Immun.*, 2000, **68**, 5084–5089.
- 45 48 P. Gargalovic and L. Dory, Caveolin-1 and caveolin-2 expression in mouse macrophages. High density lipoprotein 3-stimulated secretion and a lack of significant subcellular co-localization, *J. Biol. Chem.*, 2001, **276**, 26164–26170.
- 50 49 I. A. Khalil, K. Kogure, H. Akita and H. Harashima, Uptake pathways and subsequent intracellular trafficking in non-viral gene delivery, *Pharmacol. Rev.*, 2006, **58**, 32–45.
- 55 50 T. N. Demidova and M. R. Hamblin, Macrophage-targeted photodynamic therapy, *Int. J. Immunopathol. Pharmacol.*, 2004, **17**, 117–126.
- 50 51 M. P. Jenkins, G. Buonaccorsi, A. MacRobert, C. C. R. Bishop, S. G. Bown and J. R. McEwain, Intra-arterial photodynamic therapy using 5-ALA in a swine model, *Eur. J. Vasc. Endovasc. Surg.*, 1998, **16**, 284–291.
- 55 52 G. Di Venosa, H. Fukuda, A. Batlle, A. MacRobert and A. Casas, Photodynamic therapy: regulation of porphyrin synthesis and hydrolysis from ALA esters, *J. Photochem. Photobiol., B*, 2006, **83**, 129–136.
- 60 53 C. Peng, Y. Li, H. Liang, J. Cheng, Q. Li, X. Sun, Z. Li, F. Wang, Y. Guo, Z. Tian, L. Yang, Y. Tian, Z. Zhang and W. Cao, Detection and photodynamic therapy of inflamed atherosclerotic plaques in the carotid artery of rabbits, *J. Photochem. Photobiol., B*, 2011, **102**, 26–31.
- 65 54 O. C. Kwon, H. J. Yoon, K. H. Kim, H. T. Kim, Y. H. Yoon and J. K. Kim, Fluorescence kinetics of protoporphyrin-IX induced from 5-ALA compounds in rabbit postballoon injury model for ALA-photoangioplasty, *Photochem. Photobiol.*, 2008, **84**, 1209–1214.